Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Studies demonstrate positive data in treatment of hepatitis C

02.11.2004


Data from two ongoing studies testing new approaches for the treatment of chronic hepatitis C will be presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) this afternoon.


Presented by principal investigator Nezam Afdhal, M.D., Chief of Hepatology at Beth Israel Deaconess Medical Center (BIDMC) and Associate Professor of Medicine at Harvard Medical School, the new findings provide researchers with sufficient evidence to demonstrate promising results for hepatitis C patients who have not responded to existing therapies.

A viral infection, hepatitis C is transmitted through exposure to infected blood. The virus, which affects an estimated 4 million individuals nationwide, is able to survive and flourish inside the body by taking up residence in the liver cells, and subsequently using the cells’ inner machinery to make more copies of the virus. These in turn, infect other healthy cells.

The standard treatment for hepatitis C is a combination of interferon alfa and ribavirin, which act as anti-viral agents to eradicate the virus. According to Afdhal, the most recent advance in treatment has been the pegylation of interferon, which enables a once- a- week administration of the protein by injection and improves the ability to clear the virus. Combination therapy with pegylated interferon plus ribavirin for 24 to 48 weeks can result in eradication of the virus in about 50 percent of patients, he adds.



"When the hepatitis C virus doesn’t respond – as occurs in about half of all patients who are treated – those patients who already have cirrhosis are at a far greater risk for developing liver cancer or suffering liver failure," notes Afdhal. In fact, he says, hepatitis C is the leading cause of liver transplants in the U.S. Until now, no treatment has been available for these patients.

In his first presentation, Afdhal will describe results from the COPILOT [Colchicine versus PEG-INTRON Long-Term] study, which was designed by Afdhal and colleagues at BIDMC to test the long-term use of low-dose interferon among hepatitis C patients. Conducted at 40 sites nationwide, the findings are the first to demonstrate that the progression of hepatitis C can be prevented or delayed through long-term maintenance therapy with peginterferon alfa-2b.

According to Afdhal, researchers found that peginterferon alfa-2B reduced by 50 percent the risk of patients reaching a clinical endpoint (variceal bleeding, liver failure, liver transplantation, hepatocellular carcinoma or death) and reported the results as part of a planned two-year interim analysis of the data.

"This is a new treatment paradigm, showing for the first time that we can prevent the serious complications of liver disease," he explains. "The results found that when used in this way, the therapy reduced by half the risk of the virus advancing to cause liver damage."

The COPILOT study tested weight-based low-dose peginterferon alfa-2b (0.5 mcg/kg/wk, injected subcutaneously) against colchicine (0.6 mg orally, twice daily), an anti-inflammatory and antifibrotic medication, in 550 chronic hepatitis C patients with advanced fibrosis who had previously failed interferon-based therapies. A total of 59 patients reached a clinical verified endpoint: 39 in the colchicine group versus 20 in the peginterferon alfa-2b group (p=0.003). The annual clinical event rate was approximately five percent (7.0 percent vs. 3.5 percent for colchicine and peginterferon alfa-2b, respectively), underscoring the need for better treatments to prevent disease progression.

Afdhal noted that the low 0.5 mcg/kg weekly dose of peginterferon alfa-2b used in the study – one-third the dose used in standard combination therapy – was well tolerated by patients and spared them the side effect of developing hemolytic anemia, which is often associated with ribavirin use. "Patient adherence to their prescribed regimen is critical to success in hepatitis treatment and is an important consideration for long-term maintenance therapy," he said.

The COPILOT study was supported by Schering-Plough Corporation, manufacturer of peginterferon alfa-2b. Afdhal’s second presentation will describe results from a Phase II clinical trial of a new antiviral agent, NM283, being tested in humans for the first time.

The new drug shows activity against hepatitis C genotype 1 (HCV). One of six genotypes in existence, genotype 1 is the most predominant strain in the U.S., Japan and Western Europe, and is particularly difficult to treat.

Unlike existing therapies, which are administered by injection, NM283 is taken orally, says Afdhal, adding that it also has fewer side effects than existing agents. NM283 is the first in a new class of designer drugs, a polymerase inhibitor, specifically designed to block a step in HCV viral replication. "This drug is a new class of treatment for HCV and represents significant hope for future therapies," he noted. "Data from these clinical trials are encouraging and suggest that NM283 may prove to be another treatment option [for hepatitis C patients]." NM283 was shown to have direct and significant antiviral activity against HCV as a single agent in both Phase I and Phase II clinical trials. Combining NM283 with interferon also showed promising activity, according to Afdhal.

Bonnie Prescott | EurekAlert!
Further information:
http://www.bidmc.harvard.edu

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Bare bones: Making bones transparent

27.04.2017 | Life Sciences

Study offers new theoretical approach to describing non-equilibrium phase transitions

27.04.2017 | Physics and Astronomy

From volcano's slope, NASA instrument looks sky high and to the future

27.04.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>